After Financing Close, Biotech's Subsidiary to Operate Independently
Source: Streetwise Reports  (3/5/19)
An H.C. Wainwright & Co. report explained the purpose of the funding and how any resulting developments would positively impact the former parent company. More >

Biotech to Launch Preclinical Studies of Antibody in Eight Cancer Types
Source: Streetwise Reports  (2/27/19)
This company's new trials, preferred dosing and upcoming biologics license application submission are discussed in an H.C. Wainwright & Co. report. More >

FDA Grants Breakthrough Status to Biopharma's Lead Candidate for Liver Disease
Source: Streetwise Reports  (2/25/19)
The California firm's most advanced asset is advancing through Phase 2b, according to a ROTH Capital Partners report. More >

Biopharma's Foundation Provides for Downside Protection, Upside Realization
Source: Streetwise Reports  (2/20/19)
An H.C. Wainwright & Co. report described this Israeli firm's solid revenue picture and addressed the undervaluation of a key therapeutic candidate. More >

Biotech Identifies Antibody Drug Candidates to Target Toxic Protein Implicated in Parkinson's Disease
Source: Streetwise Reports  (2/13/19)
The Canadian company continues seeking partners to leverage its discovery and development platform. More >

Clinical Movement Expected in 2019 on Pharma Firm's 'Gene Therapy Promise'
Source: Streetwise Reports  (2/13/19)
A number of data readouts are expected in the coming months, which could derisk and accelerate development programs, according to an H.C. Wainwright & Co. report. More >

Report Highlights Biopharma's Breakthroughs on Treatment of Life-Threatening Pediatric Liver Diseases
Source: Streetwise Reports  (2/13/19)
Analyst expects "transformational year" for company with a phase 3 trial underway. More >

Biopharma's Drug Well Tolerated in Opioid Withdrawal Study
Source: Streetwise Reports  (2/9/19)
An H.C. Wainwright & Co. discussed these proof-of-concept data and described the company's planned Phase 1 study. More >

Accelerated Approval Could Be 'Game Changer' for Biotech
Source: Streetwise Reports  (2/2/19)
This Canadian company's immunotherapeutic targeting ovarian cancer could advance to market sooner, according to a Mackie Research Capital Corp. note. More >

Biotech Offers Reason for Others' Failed Trials of Potential Alzheimer's Disease Treatments
Source: Streetwise Reports  (2/2/19)
This Canadian developer of therapeutics for neurodegenerative diseases bases its opinion, in part, on its own preclinical findings. More >

Specialty Pharma 'Advances Pipeline' Ahead of Commercializing Lead Skin Therapy
Source: Streetwise Reports  (1/30/19)
LifeSci Capital reviewed the key takeaways from this Israeli firm's day-long research and development presentation. More >

Coverage Initiated on Developer of Therapies for Gastrointestinal Disorders
Source: Streetwise Reports  (1/30/19)
A ROTH Capital Partners report discussed this U.S.-based biopharma's two assets. More >

Lessons from January…This Could Make You Money Someday
Source: Daniel Carlson for Streetwise Reports  (1/30/19)
Daniel Carlson of Tailwinds Research does a deep dive into his portfolio to discern trends and lessons to be learned. More >

Anixa Doesn't Disappoint
Source: Daniel Carlson for Streetwise Reports  (1/29/19)
Daniel Carlson of Tailwinds Research explains why he has designated this company his 2019 stock of the year. More >

Early Data for Biotech's Pain Drug Candidate 'Show Promise'
Source: Streetwise Reports  (1/26/19)
An H.C. Wainwright & Co. report reviewed Phase 1b data for this nonopioid medication being developed for patients with severe pain. More >

Commercial Launch Planned for Schizophrenia Drug
Source: Streetwise Reports  (1/23/19)
A drug used to treat schizophrenic patients will launch commercially in February in the U.S. More >

Analyst: Reaction to Trial Data 'Unwarranted'
Source: Streetwise Reports  (1/23/19)
An analyst's note reviewed the recently announced study results in pancreatic cancer as well as the subsequent decline in stock price. More >

Analyst Shares 'Revelations from a Pooled Safety Analysis' of Pain Drug
Source: Streetwise Reports  (1/23/19)
An H.C. Wainwright & Co. report discussed the analgesic's safety profile and how it compares to an on-the-market competitor. More >

Phase 2 Study Begins for German Biopharma's Cancer Drug Candidate
Source: Streetwise Reports  (1/16/19)
A LifeSci Capital report discussed two current trials in which this therapeutic is being evaluated. More >

Biotech's Flu Vaccine Shows 'Superiority to Market Leader' in Data
Source: Streetwise Reports  (1/11/19)
Study findings that differentiate this product from competitors were reviewed in a Ladenburg Thalmann research report. More >

Biotech Enters License Agreement to Validate Biomarker as Alternative NASH Diagnostic
Source: Streetwise Reports  (1/5/19)
The background and justification for the deal was covered in an H.C. Wainwright & Co. report. More >

Potential Tenbagger Biopharma Displays 'Strong Start to New Year'
Source: Streetwise Reports  (1/4/19)
A ROTH Capital Partners report discussed the recent trial launch and provided upcoming catalysts for the stock. More >

Texas-Based Biopharma Gets PDUFA Date for Lead Orphan Disease Asset
Source: Streetwise Reports  (1/2/19)
An H.C. Wainwright & Co. report covered the potential timeline to market and subsequent estimated revenue for this therapeutic, which addresses a rare disorder in collagen production. More >

Coverage Initiated on Pharma 'Leveraging Large Markets with Differentiated Products'
Source: Streetwise Reports  (12/29/18)
A Ladenburg Thalmann report outlined the investment thesis for this Colorado-based life sciences firm. More >

Therapeutics Developer Secures Patents, Continues Phase 3 Trial Planning
Source: Streetwise Reports  (12/24/18)
An H.C. Wainwright & Co. report provided an update on the Q3/18 activities and achievements of this company targeting NASH. More >